Myriad Genetics, Inc. kicked off the trading day on 08/14/19 with a price decrease of -42.76%, equivalent to -$19.05 relative change for the day. Taking a more long-term approach, MYGN had a 52-week range of $22.07 to $50.44. At the time of this article’s publishing, this stock is trading at $25.50 after starting the trading session at $29.347. Moving on, the stock has demonstrated a 52-week change amounting to -33.05, alongside an S&P500 52-Week Change of -37.22. At the time of writing, this stock’s 50-day Moving Average stands at $29.67, while the 200-day Moving Average of this stock is currently $30.53.
Currently, this company’s share volume is sitting at $10,619,227, but has maintained average daily volume of $1.21M. This stock has generated an average Year to Date volume of $1.11 million, alongside an average 20-day volume of $2.12 million. This publicly-traded company’s shares outstanding now amounts to $73.99 million, simultaneously with a float of $72.51 million. The organization now has a market capitalization sitting at $1.89 billion.
Myriad Genetics, Inc.(MYGN) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Myriad Genetics, Inc.’s current insider ownership accounts for 1.40%. According to the most recent latest insider trade that took place on Aug 01 this organization’s Exec. VP International Ops exercised an option 60,000 at the rate of 23.73, making the entire transaction hit 1,423,900 in total value, affecting insider ownership by 164,871. Preceding that transaction, on Aug 01 Company’s President & C.E.O. exercised an option 137,000 at a price of 26.38, making the whole transaction’s value amount to 3,614,330. This particular insider is now the holder of 511,505 in total.
If we take a glance at the Ownership summary of Myriad Genetics, Inc.’s stock, 289 Institutional holders make up 108.08% of its total stock ownership. All together, they are the legal holders of 79,437,034 shares, which are valued at about $3,538,919,865 in total. If we focus on the top 3 stockholders for this publicly-traded organization, BLACKROCK INC. owns 12.54 million shares, with BAILLIE GIFFORD & CO in 2nd place owning 9.53 million shares and VANGUARD GROUP INC in third place with total ownership of 8.54 million shares.
Myriad Genetics, Inc. (MYGN) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on Mar-19, the organization reported $0.46 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at $0.42) by $0.04.
The corporation racked up revenue of $216.80million for the previous financial quarter, compared to the mean analyst estimate of $216.73 million. This company achieved a net margin of 2.45 while generating a return on equity of 2.03. Myriad Genetics, Inc.’s full-quarter revenue increased by 11.94%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.42 per share during the current fiscal year.
Myriad Genetics, Inc.’s EPS increase for this current 12-month fiscal period is 334.40%, and is forecasted to reach 9.75% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 16.31% through the next 5 years, which can be compared against the -4.90% growth it accomplished over the previous five years trading on the market.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Myriad Genetics, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 2.90. The company has managed to achieve an average true range (ATR) of 3.54. Alongside those, its PE Ratio stands at $140.88, and its Beta score is 0.65.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.27 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 20.71. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 1.73, whereas its price to cash per share for the last quarter landed at 2.02.
In the same vein, MYGN’s Diluted EPS (Earnings per Share) trailing twelve month was posted at 0.18, a figure that is expected to reach 0.47 in the next reported quarter, and analysts expect it will be 9.75% at the market close of one year from today’s date.